260 related articles for article (PubMed ID: 16258799)
1. [Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].
Kübler W
Z Kardiol; 2005; 94 Suppl 3():III/92-9. PubMed ID: 16258799
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness of prevention of coronary disease in Germany].
Lauterbach KW; Gerber A; Klever-Deichert G; Stollenwerk B
Z Kardiol; 2005; 94 Suppl 3():III/100-4. PubMed ID: 16258785
[TBL] [Abstract][Full Text] [Related]
3. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Pignone M; Earnshaw S; Tice JA; Pletcher MJ
Ann Intern Med; 2006 Mar; 144(5):326-36. PubMed ID: 16520473
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Moyad MA; Merrick GS
Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
[TBL] [Abstract][Full Text] [Related]
5. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
6. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
[TBL] [Abstract][Full Text] [Related]
8. Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study.
Galper BZ; Wang YC; Einstein AJ
PLoS One; 2015; 10(9):e0138092. PubMed ID: 26422204
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
van Hout BA; Simoons ML
Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
[TBL] [Abstract][Full Text] [Related]
10. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
11. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry.
Ademi Z; Reid CM; Hollingsworth B; Stoelwinder J; Steg PG; Bhatt DL; Vale M; Liew D;
Clin Ther; 2011 Oct; 33(10):1456-65. PubMed ID: 21982384
[TBL] [Abstract][Full Text] [Related]
14. Statins: cost analysis in Indian scenario from eight major clinical trials.
Sanmukhani J; Shah V
J Postgrad Med; 2010; 56(3):196-200. PubMed ID: 20739765
[TBL] [Abstract][Full Text] [Related]
15. Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Gotto AM
Atheroscler Suppl; 2007 Aug; 8(2):3-8. PubMed ID: 17588826
[TBL] [Abstract][Full Text] [Related]
16. Impact of statin guidelines on statin utilization and costs in an employer-based primary care clinic.
Gurgle HE; Schauerhamer MB; Rodriguez SA; McAdam-Marx C
Am J Manag Care; 2017 Dec; 23(12):e387-e393. PubMed ID: 29261246
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
[TBL] [Abstract][Full Text] [Related]
18. Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Gotto AM
Am J Med; 1999 Aug; 107(2A):36S-39S. PubMed ID: 10484239
[TBL] [Abstract][Full Text] [Related]
19. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
20. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.
Persell SD; Brown T; Lee JY; Shah S; Henley E; Long T; Luther S; Lloyd-Jones DM; Jean-Jacques M; Kandula NR; Sanchez T; Baker DW
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):560-6. PubMed ID: 26555123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
